Adaptive Biotechnologies Corporation

NASDAQ:ADPT

Biotechnology

Healthcare
$28.46 +3.66%

+$0.61 today

Market cap
$4.61B
Beta
2.15
P/E (TTM)
-54.5
EPS (TTM)
-$0.32
52W Low $9.96High $20.76

Volume 2.21M

Average 1.94M

ADPT Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

Adaptive Biotechnologies CorporationNASDAQ: ADPT

Capital Expenditures · Q2 FY2026 · quarter ended Jun 2026

Capital expenditures growth accelerates

Q2 FY2026 capital expenditures of $1.18M (cash outflow) rose 80.8% year over year, ahead of the +29.4% change in trailing-twelve-month capital expenditures. Sequentially, it rose 48.7% from the prior quarter. Over 3 fiscal years it compounded at -43.4% a year.

Context

  • Capital expenditures amounted to 1.1% of revenue in FY2025, down 1.0 pp from a year earlier.
  • Capital expenditures grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +80.8% holds above the trailing-twelve-month pace of +29.4%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
-$1.18M+48.7% QoQ
Last fiscal yearDec 2025
-$2.96M-19.2% YoY
LTMJun 2026
-$3.03M+29.4% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+80.8%——
1 year-19.2%——
3-year CAGR-43.4%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(2.96M) USD
Year-over-year change
+19.2%

Capital Expenditures vs competitors

How ADPT compares with its peers on the latest reported figures

  • ADPT's LTM Jun 2026 capital expenditures of $3.03M is the 5th largest of the 10 companies compared; the peer median is $2.01M.
  • Its year-over-year change of +29.4% is the 3rd highest of 10, against a peer median of -48.1%.
  • Capital expenditures amounts to 1.0% of revenue for ADPT, versus a peer median of 5.4%.
ADPT Competitors Peer median
Capital Expenditures for ADPT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LEGNLegend Biotech CorporationLTM Sep 2026$73.11M +292.9%+44.8%5.4%
ZLABZai Lab LimitedLTM Jun 2026$29.13M -44.0%-18.7%6.5%
TARSTarsus Pharmaceuticals, Inc.LTM Sep 2026$17.46M +103.6%+169.1%2.6%
BEAMBeam Therapeutics Inc.LTM Jun 2026$13.39M +24.6%-32.7%8.6%
ADPTAdaptive Biotechnologies CorporationLTM Jun 2026$3.03M +29.4%-43.4%1.0%
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026$2.01M -48.1%-11.7%0.9%
SRRKScholar Rock Holding CorporationLTM Sep 2026$202K -65.9%-17.3%35.4%
CPRXCatalyst Pharmaceuticals, Inc.LTM Mar 2026$85K -76.2%+26.0%0.0%
IRONDisc Medicine, Inc.LTM Sep 2026$20K -98.5%+83.5%—
MLYSMineralys Therapeutics, Inc.LTM Jun 2026$15K -59.5%——
Peer median (excluding ADPT) $2.01M-48.1%+7.1%5.4%

Competitors are the stored peer set for ADPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(207.28M)(200.19M)(225.25M)(159.6M)(59.5M)
Depreciation & Amortization13.95M20.92M22.23M19.26M17.83M
Deferred Income Tax00000
Stock-Based Compensation00053.61M51.48M
Change in Working Capital(56.82M)(71.55M)(46.18M)(17.45M)(57.77M)
Accounts Receivables(7.36M)(22.65M)2.03M(3.74M)(8.65M)
Inventory(5.2M)817K(2.84M)1.94M(998K)
Accounts Payables3.94M7.11M(5.41M)671K665K
Other Working Capital(48.19M)(56.83M)(39.97M)(16.32M)(48.79M)
Other Non-Cash Items57.42M66.87M92.88M8.97M1.96M
Operating Cash Flow(192.73M)(183.95M)(156.32M)(95.21M)(45.99M)
Capital Expenditures(61.75M)(16.35M)(10.7M)(3.66M)(2.96M)
Acquisitions (Net)00000
Purchases of Investments(316.54M)(278.78M)(429.56M)(244.26M)(181.71M)
Sales of Investments559.5M298.03M569.9M325.71M222.62M
Other Investing Activities00000
Investing Cash Flow181.21M2.91M129.65M77.79M37.95M
Debt Repayment0124.38M000
Common Stock Issued26.72M7.89M2.25M241K30.4M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities429K0000
Financing Cash Flow27.15M132.26M2.25M241K30.4M
Effect of Forex Changes0(260K)(534K)00
Net Change in Cash15.63M(49.04M)(24.97M)(17.18M)22.37M
Free Cash Flow(254.47M)(200.29M)(167.02M)(98.88M)(48.95M)

Adaptive Biotechnologies Corporation

NASDAQ:ADPT

Intrinsic Alpha fair value

Locked

Current Price

$28.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.